Cladribine tablets and multiple sclerosis: NICE technology appraisal

E-ISSN： 1931-227x|22|1|5-6

ISSN： 1367-7543

Source： PROGRESS IN NEUROLOGY AND PSYCHIATRY, Vol.22, Iss.1, 2018-01, pp. : 5-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cladribine for highly active relapsing multiple sclerosis

PRESCRIBER, Vol. 29, Iss. 2, 2018-02 ,pp. : 37-39

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cladribine Treatment of a Patient with Hairy Cell Leukemia and Concomitant Multiple Sclerosis

Acta Haematologica, Vol. 102, Iss. 2, 1999-10 ,pp. : 99-100

Karger

Access to resources Recommend Favorite

The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation

By Leist Thomas P. Vermersch Patrick

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2667-2676

Informa Healthcare

Access to resources Recommend Favorite

NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias

By Brown Patrick

Medicine, Health Care and Philosophy, Vol. 16, Iss. 2, 2013-05 ,pp. : 281-293

Springer Publishing Company

Access to resources Recommend Favorite

Has NICE got it right? An international perspective considering the case of Technology Appraisal No. 98 by the National Institute for Health and Clinical Excellence (NICE)

By Schlander Michael

Current Medical Research and Opinion, Vol. 24, Iss. 4, 2008-04 ,pp. : 951-966

Informa Healthcare

Access to resources Recommend Favorite